Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H41N5O4.2ClH |
| Molecular Weight | 632.621 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](CC2=CC=C(OC)C=C2)NC(=O)[C@@H](N)CC3=CN=CN3C)C4=CC=CC=C4
InChI
InChIKey=DUAOBJHRUKFKIH-YDVFRNEYSA-N
InChI=1S/C32H41N5O4.2ClH/c1-4-8-29(38)32(24-9-6-5-7-10-24)15-17-37(18-16-32)31(40)28(19-23-11-13-26(41-3)14-12-23)35-30(39)27(33)20-25-21-34-22-36(25)2;;/h5-7,9-14,21-22,27-28H,4,8,15-20,33H2,1-3H3,(H,35,39);2*1H/t27-,28+;;/m0../s1
| Molecular Formula | C32H41N5O4 |
| Molecular Weight | 559.699 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22547573 | https://www.ncbi.nlm.nih.gov/pubmed/16888084Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12646021
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22547573 | https://www.ncbi.nlm.nih.gov/pubmed/16888084
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12646021
BMS-470539 2 HCL (BMS-470539) is a potent, specific MC1R ligand. The
affinity of this molecule, as determined by [125I]NDP-MSH
competition binding experiments, was in the nanomolar
range (IC50 120 nM). BMS-470539 is a
potent, full agonist of recombinant human MC-1R, stably expressed
in CHO cells, with an EC50 of 16.8 nM and an intrinsic
activity of 88% in a cAMP accumulation assay. BMS-470539 exhibits anti-inflammatory properties following ischemia-reperfusion in the vasculature. BMS-470539 inhibits leukocyte trafficking. In mice, BMS-470539 inhibits lipopolysaccharide (LPS)-induced systemic tumour necrosis factor (TNF) release and LPS-induced leucocyte migration into the lung.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. | 2003 Mar 27 |
|
| A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice. | 2006 Oct |
|
| Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways. | 2012 Aug |
Patents
Sample Use Guides
Mice: Male BALB/c mice were dosed with BMS-
470539, as an i.v. bolus or s.c. injection at 33 umol/kg (18.47 mg/kg) in a
vehicle consisting of a 50% poly(ethylene glycol)/50% water mixture (100
ul/mouse).
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:31:21 GMT 2023
by
admin
on
Sat Dec 16 19:31:21 GMT 2023
|
| Record UNII |
4G3M9MP8GH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2341796-82-3
Created by
admin on Sat Dec 16 19:31:21 GMT 2023 , Edited by admin on Sat Dec 16 19:31:21 GMT 2023
|
PRIMARY | |||
|
60210130
Created by
admin on Sat Dec 16 19:31:21 GMT 2023 , Edited by admin on Sat Dec 16 19:31:21 GMT 2023
|
PRIMARY | |||
|
4G3M9MP8GH
Created by
admin on Sat Dec 16 19:31:21 GMT 2023 , Edited by admin on Sat Dec 16 19:31:21 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
